Bulletin
Investor Alert

ACADIA Pharmaceuticals Inc.

NAS: ACAD

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jan 21, 2022, 6:14 p.m.

/zigman2/quotes/205236646/composite

$

20.72

Change

-0.46 -2.17%

Volume

Volume 198,408

Quotes are delayed by 20 min

/zigman2/quotes/205236646/composite

Previous close

$ 21.49

$ 21.18

Change

-0.31 -1.44%

Day low

Day high

$20.94

$22.05

Open

52 week low

52 week high

$15.68

$54.58

Open

Annual Financials for ACADIA Pharmaceuticals Inc.

Fiscal year is January-December. All values USD millions. 20162017201820192020 5-year trend
Sales/Revenue 17.33M124.9M223.81M339.08M441.76M
Cost of Goods Sold (COGS) incl. D&A 3.08M9.08M12.38M11.34M11.69M
COGS excluding D&A 1.25M6.36M9.37M8.58M8.76M
Depreciation & Amortization Expense 1.83M2.71M3.01M2.77M2.93M
Depreciation 843,0001.24M1.53M1.29M1.46M
Amortization of Intangibles 985,0001.48M1.48M1.48M1.48M
Gross Income 14.26M115.82M211.43M327.73M430.07M
20162017201820192020 5-year trend
SG&A Expense 285.74M404.25M458.87M574.28M663.85M
Research & Development 99.28M149.19M187.16M240.39M266.33M
Other SG&A 186.46M255.06M271.71M333.89M397.52M
Other Operating Expense 1.33M3.98M---
Unusual Expense ----52.8M
EBIT after Unusual Expense ----(286.59M)
Non Operating Income/Expense --(1.84M)997,000(997,000)
Non-Operating Interest Income 2.76M4.13M5.35M11.17M6.61M
Equity in Affiliates (Pretax) -----
Interest Expense -----
Gross Interest Expense -----
Interest Capitalized -----
Pretax Income (270.05M)(288.28M)(243.94M)(234.38M)(280.97M)
Income Tax 1.34M1.12M1.26M876,000611,000
Income Tax - Current Domestic -----
Income Tax - Current Foreign -----
Income Tax - Deferred Domestic -----
Income Tax - Deferred Foreign -----
Income Tax Credits -----
Equity in Affiliates -----
Other After Tax Income (Expense) -----
Consolidated Net Income (271.39M)(289.4M)(245.19M)(235.26M)(281.58M)
Minority Interest Expense -----
Net Income (271.39M)(289.4M)(245.19M)(235.26M)(281.58M)
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries (271.39M)(289.4M)(245.19M)(235.26M)(281.58M)
Preferred Dividends -----
Net Income Available to Common (271.39M)(289.4M)(245.19M)(235.26M)(281.58M)
EPS (Basic) (2.34)(2.36)(1.94)(1.60)(1.79)
Basic Shares Outstanding 115.86M122.6M126.58M147.2M157.33M
EPS (Diluted) (2.34)(2.36)(1.94)(1.60)(1.79)
Diluted Shares Outstanding 115.86M122.6M126.58M147.2M157.33M
EBITDA (270.99M)(289.7M)(244.44M)(243.78M)(230.85M)
Link to MarketWatch's Slice.